Aterocor, Inc. , a company developing an innovative treatment for adrenal cancer, today announced $16 million in Series A venture capital financing. Frazier Healthcare and 5AM Ventures led the round and the proceeds from the financing will support the accelerated development of Atterocor’s lead programme.
“We’re excited to launch Atterocor with this Series A funding that will enable us to move our lead program to the clinic quickly and efficiently,” said Julia Owens, Ph.D. D. D. , founder, president and chief executive officer of Atterocor; “Adrenal cancer is a rare disease for which there are very limited treatment options and a critical need for a patient. Now that we have secured funding for this program, we will continue to focus on achieving key corporate and clinical development milestones and look forward to providing updates on our future progress. “That’s right.
Dr. Joining The founders of the company are Raili Kerppola, Ph. D. D. , MBA, serving as Chief Operating Officer and Gary Hammer, M. D. D. Ph, Ph. D. D. Millie Schembechler is Professor of Adrenal Cancer, Director of the Endocrine Oncology Program and Director of the Center for Organogenesis at the University of Michigan, and will serve as Scientific Advisor to the Company.
Adrenal cancer is often diagnosed at a late stage of the disease when the patient’s prognosis is very poor. This form of cancer is rare in approximately 600 U-diagnosed patients. Oh, S Every year, Current treatment options are extremely limited and are often ineffective and poorly tolerated in many patients.
About Aterocor, Inc.
Atterocor is a drug development company focused on novel treatments for adrenal cancer. The company was launched in 2012 with Series A financing led by top-tier life science investors Frazier Healthcare and 5AM Ventures. Atterocor is located in Ann Arbor, Michigan.
Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/Atterocor/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co
